Last reviewed · How we verify
Lucentis
Lucentis is a Small molecule drug developed by Santen Inc.. It is currently FDA-approved for Age related macular degeneration, Branch retinal vein occlusion with macular edema, Central retinal vein occlusion with macular edema. Also known as: Ranibizumab, ranibizumab, Aqueous Tap, Reference Product.
At a glance
| Generic name | Lucentis |
|---|---|
| Also known as | Ranibizumab, ranibizumab, Aqueous Tap, Reference Product, Ranibizumab Injection |
| Sponsor | Santen Inc. |
| Target | Vascular endothelial growth factor A |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- Age related macular degeneration
- Branch retinal vein occlusion with macular edema
- Central retinal vein occlusion with macular edema
- Choroidal retinal neovascularization
- Diabetic retinopathy
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
- Retinopathy of prematurity
Common side effects
- Conjunctival hemorrhage
- Cataract
- Eye pain
- Intraocular pressure increased
- Vitreous detachment
- Vitreous floaters
- Foreign body sensation in eyes
- Intraocular inflammation
Serious adverse events
- Endophthalmitis
- Rhegmatogenous retinal detachment
- Iatrogenic traumatic cataract
- Thromboembolic events
- Fatal events in patients with DME and DR at baseline
- Tear of retinal pigment epithelium
- Wound healing complications
- Iritis
- Vitritis
Key clinical trials
- Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) (PHASE4)
- A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (PHASE3)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lucentis CI brief — competitive landscape report
- Lucentis updates RSS · CI watch RSS
- Santen Inc. portfolio CI
Frequently asked questions about Lucentis
What is Lucentis?
Lucentis is a Small molecule drug developed by Santen Inc., indicated for Age related macular degeneration, Branch retinal vein occlusion with macular edema, Central retinal vein occlusion with macular edema.
What is Lucentis used for?
Lucentis is indicated for Age related macular degeneration, Branch retinal vein occlusion with macular edema, Central retinal vein occlusion with macular edema, Choroidal retinal neovascularization, Diabetic retinopathy.
Who makes Lucentis?
Lucentis is developed and marketed by Santen Inc. (see full Santen Inc. pipeline at /company/santen-inc).
Is Lucentis also known as anything else?
Lucentis is also known as Ranibizumab, ranibizumab, Aqueous Tap, Reference Product, Ranibizumab Injection.
What development phase is Lucentis in?
Lucentis is FDA-approved (marketed).
What are the side effects of Lucentis?
Common side effects of Lucentis include Conjunctival hemorrhage, Cataract, Eye pain, Intraocular pressure increased, Vitreous detachment, Vitreous floaters. Serious adverse events: Endophthalmitis, Rhegmatogenous retinal detachment, Iatrogenic traumatic cataract, Thromboembolic events.
What does Lucentis target?
Lucentis targets Vascular endothelial growth factor A.
Related
- Target: All drugs targeting Vascular endothelial growth factor A
- Manufacturer: Santen Inc. — full pipeline
- Therapeutic area: All drugs in Metabolic
- Indication: Drugs for Age related macular degeneration
- Indication: Drugs for Branch retinal vein occlusion with macular edema
- Indication: Drugs for Central retinal vein occlusion with macular edema
- Also known as: Ranibizumab, ranibizumab, Aqueous Tap, Reference Product, Ranibizumab Injection